Impact of Ad Exposure Frequency on Perception and Mental Processing of Risk and Benefit Information in Direct-to-Consumer Prescription Drug Ads

ICR 201506-0910-030

OMB: 0910-0803

Federal Form Document

Forms and Documents
Document
Name
Status
Supporting Statement B
2015-06-29
Supporting Statement A
2015-06-29
ICR Details
0910-0803 201506-0910-030
Historical Active
HHS/FDA CDER
Impact of Ad Exposure Frequency on Perception and Mental Processing of Risk and Benefit Information in Direct-to-Consumer Prescription Drug Ads
New collection (Request for a new OMB Control Number)   No
Regular
Approved without change 09/30/2015
Retrieve Notice of Action (NOA) 06/29/2015
  Inventory as of this Action Requested Previously Approved
09/30/2018 36 Months From Approved
8,970 0 0
1,954 0 0
0 0 0

The purpose of this study is to examine effects of variation in exposure frequency to direct-to-consumer (DTC) prescription drug television ads. We plan to conduct up to two pretests with 105 individuals each, with adults who self-identify as having been diagnosed with seasonal allergies. Following the pretests, we plan to conduct the main study with 600 adults who self-identify as having been diagnosed with seasonal allergies. In the pretests and main study, participants will view a DTC ad for seasonal allergies one, two, or four times, depending on the experimental condition. The DTC ad will be embedded in clutter reels and presented as part of 42 minutes of television programming. Combined, the television show and clutter reels will make up a 60-minute television package. After viewing the stimuli, participants will complete a questionnaire that will include measures of perception, memory, judgments about the ad, intentions to use the medication advertised, and possible moderators of effects, such as need for cognition and demographics.

US Code: 42 USC 300u(a)(4) Name of Law: Public Health Service Act
   US Code: 21 USC 393(b)(2)(c) Name of Law: Federal Food, Drug, and Cosmetic Act
  
None

Not associated with rulemaking

  79 FR 67172 11/12/2014
80 FR 34672 06/17/2015
Yes

  Total Approved Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 8,970 0 0 8,970 0 0
Annual Time Burden (Hours) 1,954 0 0 1,954 0 0
Annual Cost Burden (Dollars) 0 0 0 0 0 0
Yes
Miscellaneous Actions
No
This is a new data collection.

$1,198,806
Yes Part B of Supporting Statement
No
No
No
No
Uncollected
Ila Mizrachi 301 796-7726 ila.mizrachi@fda.hhs.gov

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
06/29/2015


© 2024 OMB.report | Privacy Policy